These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 38070973)
21. A Simplified Semiquantitative Meal Bolus Strategy Combined with Single- and Dual-Hormone Closed-Loop Delivery in Patients with Type 1 Diabetes: A Pilot Study. Gingras V; Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R Diabetes Technol Ther; 2016 Aug; 18(8):464-71. PubMed ID: 27191385 [TBL] [Abstract][Full Text] [Related]
22. Lived experience of older adults with type 1 diabetes using closed-loop automated insulin delivery in a randomised trial. Kubilay E; Trawley S; Ward GM; Fourlanos S; Grills CA; Lee MH; MacIsaac RJ; O'Neal DN; O'Regan NA; Sundararajan V; Vogrin S; Colman PG; McAuley SA Diabet Med; 2023 Apr; 40(4):e15020. PubMed ID: 36468784 [TBL] [Abstract][Full Text] [Related]
23. [Technological innovations in the treatment of type 1 diabetes in pediatrics]. Tubiana-Rufi N Soins Pediatr Pueric; 2016; (288):38-40. PubMed ID: 26776695 [TBL] [Abstract][Full Text] [Related]
24. Insulin Therapy and Diabetic Pregnancy. Napoli A Am J Ther; 2020; 27(1):e91-e105. PubMed ID: 31688066 [TBL] [Abstract][Full Text] [Related]
25. Glycemic Outcomes in Baseline Hemoglobin A1C Subgroups in the International Diabetes Closed-Loop Trial. Ekhlaspour L; Town M; Raghinaru D; Lum JW; Brown SA; Buckingham BA Diabetes Technol Ther; 2022 Aug; 24(8):588-591. PubMed ID: 35020488 [TBL] [Abstract][Full Text] [Related]
26. Closed-Loop Artificial Pancreas Therapy for Type 1 Diabetes. Zhou K; Isaacs D Curr Cardiol Rep; 2022 Sep; 24(9):1159-1167. PubMed ID: 35727409 [TBL] [Abstract][Full Text] [Related]
27. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial. Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323 [TBL] [Abstract][Full Text] [Related]
28. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. Stewart ZA; Wilinska ME; Hartnell S; Temple RC; Rayman G; Stanley KP; Simmons D; Law GR; Scott EM; Hovorka R; Murphy HR N Engl J Med; 2016 Aug; 375(7):644-54. PubMed ID: 27532830 [TBL] [Abstract][Full Text] [Related]
29. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial. Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750 [TBL] [Abstract][Full Text] [Related]
30. A clinical review of the t:slim X2 insulin pump. Berget C; Lange S; Messer L; Forlenza GP Expert Opin Drug Deliv; 2020 Dec; 17(12):1675-1687. PubMed ID: 32842794 [TBL] [Abstract][Full Text] [Related]
31. Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial. Tauschmann M; Allen JM; Wilinska ME; Thabit H; Stewart Z; Cheng P; Kollman C; Acerini CL; Dunger DB; Hovorka R Diabetes Care; 2016 Jul; 39(7):1168-74. PubMed ID: 26740634 [TBL] [Abstract][Full Text] [Related]
32. Commercial hybrid closed-loop systems available for a patient with type 1 diabetes in 2022. Seget S; Tekielak A; Rusak E; Jarosz-Chobot P Pediatr Endocrinol Diabetes Metab; 2023; 29(1):30-36. PubMed ID: 37218723 [TBL] [Abstract][Full Text] [Related]
33. Diabetes and Technology. Simmons K; Riddley S Prim Care; 2022 Jun; 49(2):327-337. PubMed ID: 35595486 [TBL] [Abstract][Full Text] [Related]
34. Overnight Counter-Regulatory Hormone Levels and Next Day Glycemia in Adults with Type 1 Diabetes During Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump with Low-Glucose Suspend. Graf A; Ward GM; Vogrin S; Sundararajan V; Sharifi A; De Bock MI; Jayawardene D; Loh MM; Horsburgh JC; Berthold CL; Paramalingam N; Bach LA; Colman PG; Davis EA; Grosman B; Jenkins AJ; Kumareswaran K; Kurtz N; Kyoong A; MacIsaac RJ; Roy A; Jones TW; O'Neal DN Diabetes Technol Ther; 2017 Jul; 19(7):438-439. PubMed ID: 28537427 [No Abstract] [Full Text] [Related]
35. Who Should Access Closed-Loop Technology? A Qualitative Study of Clinician Attitudes in England. Farrington C; Hovorka R; Murphy HR Diabetes Technol Ther; 2020 May; 22(5):404-410. PubMed ID: 31913061 [No Abstract] [Full Text] [Related]
36. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039 [TBL] [Abstract][Full Text] [Related]
37. Impact of the CamAPS FX hybrid closed-loop insulin delivery system on sleep traits in older adults with type 1 diabetes. Thabit H; Boughton C; Mubita W; Rubio J; Mader JK; Narendran P; Evans M; Leelarathna L; Wilinska ME; Fullwood C; Gregory AM; Hovorka R; Rutter MK Diabetes Obes Metab; 2023 Mar; 25(3):889-893. PubMed ID: 36335565 [No Abstract] [Full Text] [Related]